Malignant melanoma is the most aggressive type of skin cancer with invasive growth patterns. Recent advances in melanoma management have focused on cell growth, proliferation, migration, and survival biomarkers. Numerous FDA-approved molecular-targeted therapies, such as tyrosine kinase inhibitors (TKIs), have been developed targeting genetic biomarkers that play a critical role in tumorigenesis when overexpressed. The use of targeted therapies as an alternative or adjuvant to immunotherapy has revolutionized the management of metastatic melanoma. Although this treatment strategy is more efficacious and less toxic than traditional therapies, targeted therapies are less effective after prolonged treatment due to acquired resistance given the mutations and activation of resistant mechanisms in melanoma tumors. In this sense, identifying novel target therapies and repositioned drugs that could modulate the disease progression, the potential molecular and pharmacological mechanisms of therapies are of utmost interest.

The past few years have witnessed an astonishing international effort that established the role of some 20 new molecules in apoptosis and added activation or suppression of apoptosis to the accepted biological functions of a great many others already familiar in cancer biology. Some of these molecules are receptors, transducing cytokine-mediated signals; others appear to intensify or diminish the risk that a compro mised cell will fire its apoptosis effector mechanism. All are of interest as potential targets for tumor therapy, and some may prove to be control points influenced in the pathogenesis of cancer and other diseases as diverse as viral infection, neurodegenerative disorders, and stroke. Sometimes, in the midst of these developments, a kind of euphoria ap pears to have gripped the research community, with the expectation that apoptosis will afford explanations to many unsolved questions in cellu lar regulation. This book, in a series of thoughtful and provocative ar ticles--some from established leaders in the field, and others from younger scientists--seeks to redress the balance.

From its introduction, oncological chemotherapy has been encumbered by poor selectivity because antiproliferative drugs are often toxic not only to tumor cells but also to important populations of the body’s non-neoplastic cells. Modern targeted therapies interact with defined molecules present on cancer cells, adding increased selectivity to their toxic effects. This book presents an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach.

Animal Models in Cancer Drug Discovery brings forward the most cutting-edge developments in tumor model systems for translational cancer research. The reader can find under this one volume virtually all types of existing and emerging tumor models in use by the research community. This book provides a deeper insight on how these newer models could de-risk modern drug discovery. Areas covered include up to date information on latest organoid derived models and newer genetic models. Additionally, the book discusses humanized animal tumor models for cancer immunotherapy and how they leverage personalized therapies. The chapter on larger animal, canine models and their use in and their use in pre-investigational new drug (pre-IND) development makes the volume unique. Unlike before, the incorporation of several simplified protocols, breeding methodologies, handling and assessment procedures to study drug intervention makes this book a must read. Animal Models in Cancer Drug Discovery is a valuable resource for basic and translational cancer researchers, drug discovery researchers, contract research organizations, and knowledge seekers at all levels in the biomedical field.

Mohs surgery is microscopically controlled surgery used to treat common types of skin cancer and allows for the removal of a skin cancer with a very narrow surgical margin and a high cure rate. However, for those involved with the Mohs procedure, it is critical to understand the optimal preparation and interpretation of frozen sections. Complete with hundreds of high resolution figures, Atlas of Practical Mohs Histopathology is written by leading experts in the field and discusses everything from normal skin histology and rare tumors to pitfalls and incidental findings. Dermatologic surgeons, Mohs cutaneous surgeons, dermatopathologists and pathologists alike will find this book to be a comprehensive and indispensable reference.

Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates